Witryna1 dzień temu · Immunic Inc CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase... April 13, 2024 Witryna5 maj 2024 · NEW YORK, May 5, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the start of the patient cohorts in its ongoing phase 1 …
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase …
Witryna9 lut 2024 · NEW YORK, Feb. 9, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral … WitrynaKey secondary endpoints include volume of new T2-lesions, time to confirmed disability progression, time to sustained clinically relevant changes in cognition, and percentage of whole brain volume change, grey matter volume, and white matter volume. ... Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in … dan harris meltdown on good morning america
Immunic reports another trial flop, and execs blame ‘confounded ...
Witryna3 lis 2024 · NEW YORK, Nov. 3, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating ... Witryna11 kwi 2024 · The trading price of Immunic Inc. (NASDAQ:IMUX) closed lower on Monday, April 10, closing at $1.33, -4.32% lower than its previous close. In examining the 52-week price action we see that the stock hit a 52-week high of $12.22 and a 52-week low of $1.11. ... According a new report published by BloombergNEF on investment in … Witryna17 lis 2024 · NEW YORK, Nov. 17, 2024 /PRNewswire/ --Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral … dan harrison custom knives